LISATA THERAPEUTICS, INC.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$352M
Investors
20
Min Invest
None stated
What this filing shows
·Every sentence is a value as filed on SEC Form D
LISATA THERAPEUTICS, INC. is a Delaware corporation that filed a Form D with the SEC on October 2, 2026 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. LISATA THERAPEUTICS, INC. reported $351,903,103 sold from 20 investors of a $351,903,103 total offering as of the Form D filed October 2, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports 20 non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names H.C.WAINWRIGHT & CO., LLC (CRD 375), associated with None; LEERINK PARTNERS LLC (CRD 39011), associated with None; LIFESCI CAPITAL (CRD 168404), associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $2,600,000 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
2
latest Oct 2, 2026
Critical / warning
0 / 2
0 watch · 0 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
7
closed, lapsed
Latest event New filer · Oct 2, 2026
SEC.govInvestor
- 2 filing events with values and deltas, latest 2026-10-02, and alerts on the next one
- 7 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2026-10-02: 6 related persons added and 5 removed against the filing of 2021-02-01; 9 now listed. The names are in the Terminal feed.
DAVID MAZZO
Executive Officer, Director · BASKING RIDGE, NJ
JAMES NISCO
Executive Officer · BASKING RIDGE, NJ
TARIQ IMAM
Executive Officer · BASKING RIDGE, NJ
GREGORY BROWN
Director · BASKING RIDGE, NJ
HEIDI HENSON
Director · BASKING RIDGE, NJ
CYNTHIA FLOWERS
Director · BASKING RIDGE, NJ
STEVEN KLOSK
Director · BASKING RIDGE, NJ
MOHAMMAD AZAB
Director · BASKING RIDGE, NJ
TED LOVE
Director · BASKING RIDGE, NJ
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
H.C.WAINWRIGHT & CO., LLCCRD 375 on BrokerCheck
Associated broker-dealer: None · NEW YORK, NY · Soliciting in all states
LEERINK PARTNERS LLCCRD 39011 on BrokerCheck
Associated broker-dealer: None · BOSTON, MA · Soliciting in all states
LIFESCI CAPITALCRD 168404 on BrokerCheck
Associated broker-dealer: None · NEW YORK, NY · Soliciting in all states
Questions About LISATA THERAPEUTICS, INC.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is LISATA THERAPEUTICS, INC.?
LISATA THERAPEUTICS, INC. is a Delaware corporation that filed a Form D with the SEC on October 2, 2026 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.
Is LISATA THERAPEUTICS, INC. legit?
AltStreet does not rate legitimacy; it reports the public record. LISATA THERAPEUTICS, INC. filed a Form D with the SEC on October 2, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $351,903,103 sold to 20 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is LISATA THERAPEUTICS, INC. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that LISATA THERAPEUTICS, INC. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has LISATA THERAPEUTICS, INC. raised?
LISATA THERAPEUTICS, INC. reported $351,903,103 sold from 20 investors of a $351,903,103 total offering as of the Form D filed October 2, 2026.
Who can invest in LISATA THERAPEUTICS, INC.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports 20 non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in LISATA THERAPEUTICS, INC.?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling LISATA THERAPEUTICS, INC. and how are they paid?
The Form D names H.C.WAINWRIGHT & CO., LLC (CRD 375), associated with None; LEERINK PARTNERS LLC (CRD 39011), associated with None; LIFESCI CAPITAL (CRD 168404), associated with None as recipients of sales compensation soliciting in all states. Sales commissions are reported as $2,600,000 and finders' fees as $0. Form D allows these to be estimates.
Who is behind LISATA THERAPEUTICS, INC.?
The Form D lists 9 related persons: DAVID MAZZO, executive officer, director; JAMES NISCO, executive officer; TARIQ IMAM, executive officer; GREGORY BROWN, director; HEIDI HENSON, director; CYNTHIA FLOWERS, director; STEVEN KLOSK, director; MOHAMMAD AZAB, director, and 1 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is LISATA THERAPEUTICS, INC. located?
The issuer's address on its SEC filings is 110 Allen Road, Second Floor, Basking Ridge, NJ 07920. Its phone number of record is 908-229-2590. It is organized under the laws of Delaware.
How long is the LISATA THERAPEUTICS, INC. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is LISATA THERAPEUTICS, INC.'s revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is LISATA THERAPEUTICS, INC. raising money for an acquisition?
Yes. The Form D indicates that the offering is being made in connection with a business combination transaction, such as a merger or acquisition.
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.